In the coming days the Precision Nanomedicine journal will see the light, in its online version that is already being finalised. Dr. Simón Schwartz Jr, director of CIBBIM-Nanomedicine, is one of only two Spanish researchers who are part of the...
Read more
One of the main problems that nanomedicine must face is the improvement of drugs transport and release systems to the correct place of action. And in particular, to take nucleic acids to the right target cells. The team led by Dr. Simó Schwartz...
Read more
This January, the Area of Functional Validation & Preclinical Research (FVPR) of CIBBIM-Nanomedicine has obtained the ISO 9001:2008 certification of Quality Management Systems for functional validation, preclinical development and/or...
Read more
Asdent (Association of Dent Disease) has delivered 114,978.55 euros to the Vall d’Hebron Research Institute (VHIR) to continue researching this disease. The pathology of Dent is a hereditary minority disease linked to the X chromosome and...
Read more
The national consortium led by the research group of Addressing and Drug Release CIBBIM - Nanomedicine of the Vall d’Hebron Research Institute (VHIR) and led by Dr. Ibane Abasolo, has shown improvement in the effectiveness and...
Read more
A study led by Dr. Anna Meseguer, chief of the group of research CIBBIM-Nanomedicine Renal Pathophysiology of the Vall d’Hebron Research Institute (VHIR), has showed the role of the KAP protein in the control of the development of the metabolic...
Read more
Last September, the journal of Immunology published a new article in the series «The Pillars of Immunology», which reminds the classics that have promoted the knowledge of modern immunology. In this case, the study published has been based in the...
Read more
The European Union has awarded a grant of 6,8 million Euro to nTRACK collaborative project, which will officially be launched on the 16th of October in Barcelona. The goal of the nTRACK project is to develop a highly sensitive multimodal...
Read more
El projecte ThermoShot™-FlashShot™: Nova tecnologia per combatre les infeccions multiresistents o les produïdes per dispositius mèdics que produeixen biopel·lícules forma part dels 23 treballs seleccionats en la tercera convocatòria del Programa...
Read more
NANBIOSIS-U20 Scientific Director, Simó Schwartz, speaks about Nanomedicine in an interview publish in http://www.quimicaysociedad.org. NANBIOSIS is an Singular Scientific Technological Infrastructure (ICTS) that provides a complete service for...
Read more
The European Nanomedicine Characterisation Laboratory (EU-NCL) has selected a project from VHIR intended to develop a therapeutic nanoconjugate that improves the treatment of prostate cancer. The project is coordinated by Dr. Simó Schwartz Jr...
Read more
Can we improve the treatment of cancer with the help of nanoparticles? How can we help improve the effectiveness of a drug? Which treatment works best? And how can we test it? These are some of the questions that the group if Functional...
Read more
